Mesenchymal Stem Cell Therapy in Acute Liver Failure

Acute liver failure (ALF) is a severe liver disease syndrome with rapid deterioration and high mortality. Liver transplantation is the most effective treatment, but the lack of donor livers and the high cost of transplantation limit its broad application. In recent years, there has been no breakthro...

Full description

Saved in:
Bibliographic Details
Published inGut and liver Vol. 17; no. 5; pp. 674 - 683
Main Authors Yong-hong Wang, En-qiang Chen
Format Journal Article
LanguageKorean
Published 대한소화기학회 30.09.2023
Subjects
Acute liver failure
Hepatocyte-like cells
Immunomodulation
Mesenchymal stem cells
Online AccessGet full text

Cover

More Information
Summary:Acute liver failure (ALF) is a severe liver disease syndrome with rapid deterioration and high mortality. Liver transplantation is the most effective treatment, but the lack of donor livers and the high cost of transplantation limit its broad application. In recent years, there has been no breakthrough in the treatment of ALF, and the application of stem cells in the treatment of ALF is a crucial research field. Mesenchymal stem cells (MSCs) are widely used in disease treatment research due to their abundant sources, low immunogenicity, and no ethical restrictions. Although MSCs are effective for treating ALF, the application of MSCs to ALF needs to be further studied and optimized. In this review, we discuss the potential mechanisms of MSCs therapy for ALF, summarize some methods to enhance the efficacy of MSCs, and explore optimal approaches for MSC transplantation. (Gut Liver 2023;17:674-683)
Bibliography:Korean Society of Gastroenterology
ISSN:1976-2283